Nummular eczema (NE) is a chronic, pruritic dermatitis with substantial patient burden and no FDA-approved therapies. Emerging data suggest that biologics and small-molecule inhibitors may be promising therapeutic options for NE.

Pigmentary disorders, including hyperpigmentation, are among the most common dermatologic diagnoses in individuals with skin of color (SOC), particularly individuals with African, Asian, or Hispanic heritage, and often carry a significant quality-of-life burden. Although the evidence base has grown, gaps persist in epidemiology, in pathophysiology-driven treatment selection, and in the appropriate representation of Fitzpatrick skin types III to VI in clinical studies.

Nummular eczema (NE) is a prevalent and chronic inflammatory dermatosis marked by pruritic, coin-shaped eczematous plaques. Contact allergen sensitization may play a role in NE etiology.

Melanoma is a dynamic health problem caused by deteriorating melanocytes that generate aberrant melanin that gives color to the skin. It remains the leading cause of death from skin cancer. The incidence and mortality rates of melanoma emphasize the need for a suitable diagnostic biopsy, which is important for the optimal treatment of newly observed melanoma patients.